Immunosuppressants - Estonia

Estonia

The Immunosuppressants market in Estonia is anticipated to achieve a revenue of US$9.11m by 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 15.43%, leading to a market volume of US$18.67m by 2029.
When compared globally, the largest share of revenue is expected to be generated United States, reaching a staggering US$35,470.00m by 2024.
Despite the small size of Estonia's pharmaceutical market, the demand for immunosuppressants is steadily increasing due to the growing prevalence of autoimmune diseases in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Estonia has been on a steady rise in recent years.

Customer preferences: Immunosuppressants are primarily used to prevent organ rejection in transplant patients and to treat autoimmune disorders. The aging population, increased incidence of chronic diseases, and improved healthcare facilities have contributed to the growing demand for immunosuppressants in Estonia. Patients in Estonia prefer to use generic immunosuppressants due to their cost-effectiveness.

Trends in the market: The Estonian government has been taking measures to ensure the availability of affordable immunosuppressants to patients. The government has been negotiating with pharmaceutical companies to reduce the prices of immunosuppressants. Additionally, the government has been promoting the use of biosimilars, which are cheaper alternatives to biologic immunosuppressants. The increasing use of biosimilars in Estonia has contributed to the growth of the immunosuppressants market.

Local special circumstances: Estonia is a small country with a population of 1.3 million. The small market size makes it challenging for pharmaceutical companies to introduce new drugs into the market. However, the Estonian government has been proactive in promoting the use of generic and biosimilar drugs, which has helped to increase the availability of immunosuppressants in the country.

Underlying macroeconomic factors: Estonia has a relatively high incidence of chronic diseases such as cardiovascular diseases, cancer, and diabetes. The prevalence of chronic diseases has been increasing due to the aging population and unhealthy lifestyles. The Estonian government has been investing in healthcare infrastructure and services to address the growing healthcare needs of the population. The government's efforts to improve healthcare facilities have contributed to the growth of the immunosuppressants market in Estonia.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.